tbuckley/cabot-search huggingface dataset:
RO-ILS: Radiation Oncology Incident Learning System data trends 2014-2015.
Authors: David J. Hoopes, Eric C. Ford, Nadine L. Eads, Ksenija Kapetanovic, Cindy Tomlinson
Journal: Journal of Clinical Oncology (2016)

59 Background: Incident learning is one of the most effective ways to improve quality care. To facilitate patient safety improvement at a national level, American Society for Radiation Oncology (ASTRO) and American Association of Physicists in Medicine (AAPM) launched RO-ILS: Radiation Oncology Incident Learning System in June 2014. RO-ILS mission is to facilitate safer and higher quality care through a shared learning environment that is secure and non-punitive. Methods: To ensure the security and protection of data, ASTRO contracted with Clarity PSO, a federally-certified patient safety organization that operates under the auspices of the Patient Safety and Quality Improvement Act of 2005. Radiation oncology practices sign a no-fee contract with Clarity PSO to participate in RO-ILS and then enter safety data into a customized web-based portal. Submitted data are analyzed and interpreted by the Radiation Oncology Healthcare Advisory Council (RO-HAC), a multi-professional team. Practices receive aggregate quarterly reports and institutional reports when substantial data are submitted. Results: During the first year, 61 US practices (123) facilities signed contracts. 42 practices entered 1259 events and 619 of these events (49%) were submitted to the national database. Types of events included: 242 (39%) incidents that reached the patient with or without harm; 206 (33%) near-misses; and 171 (28%) unsafe conditions. RO-HAC identified risk-prone processes including ineffective communication, compressed timelines to start treatment, changes to treatment during the course of therapy and junior practitioners’ errors not remedied by experienced staff. Conclusions: Data suggests that quality assurance processes were effective in catching errors; however, continued work needs to address the origin of these errors and suggest robust solutions. To facilitate improved communication, effective protocols and software enhancements are recommended to alert staff to changes in patients’ management. Policies and procedures on patient hand-offs, emergency cases and oversight of junior staff will help error mitigation. While in its infancy, RO-ILS provides useful data and will serve to improve the quality and safety of radiotherapy.
Identification of Molecular Defects in ITGA2B and ITGB3 Genes and Phenotypic Correlation in Pakistani Patients with Glanzmann Thrombasthenia
Authors: Yonus Jamal, Shariq Ahmed, Akbar Najmuddin, Ayisha Imran, Tehmina nafees sonia Khan, Tahir Shamsi, Arshi Naz
Journal: Blood (2015)
Phase Ib Multicenter Dose Escalation Study of Carfilzomib Plus Lenalidomide and Low Dose Dexamethasone (CRd) in Relapsed and Refractory Multiple Myeloma (MM).
Authors: Ruben Niesvizky, Luhua Wang, Robert Z Orlowski, William Bensinger, Melissa Alsina, Nashat Gabrail, Andres Gutierrez, Lori Kunkel, Michael Kauffman
Journal: Blood (2009)
Feasibility and potential benefits of second-line chemotherapy in patients with advanced biliary tract cancer.
Authors: Thomas Walter, Anne M. Horgan, Elizabeth McKeever, Trisha Min, Mairead McNamara, David W Hedley, Stefano Serra, Monika K. Krzyzanowska, Eric Xueyu Chen, Helen Mackay, Ronald Feld, Malcolm J. Moore, Jennifer J. Knox
Journal: Journal of Clinical Oncology (2012)

338 Background: Chemotherapy is effective in metastatic or unresectable biliary tract cancer (BTC). The benefits of second-line chemotherapy (CT2) are unclear. Methods: We retrospectively studied all patients (pts) receiving at least one cycle of chemotherapy for advanced BTC at our institution between 1991 and 2011. We analyzed pt and chemotherapy characteristics (type of regimen; tumor response; time to progression (TTP); and overall survival (OS)). The objectives were: 1) to characterize pts eligible for CT2; 2) to evaluate the efficacy of CT2. Results: 367, 89 (24%), and 24 (6%) pts received CT1, CT2, and CT3, respectively. Primary tumor location was the gallbladder (30%), intraphepatic (16%), perihilar (20%), distal common bile duct (20%), and ampulla of Vater (14%). 88% had a baseline performance status of 0-1 prior to CT1. The regimen and efficacy data of CT1 and CT2 are presented in the Table . On univariate analysis females (p=0.002) and pts with TTP &gt;6 months on CT1 (p=0.016) were the only variables associated with receiving CT2. The only factor associated with disease control (objective response+ stable disease) on CT2 was the regimen type (75% with a doublet versus 46% with monotherapy, p=0.03). Conclusions: Among patients with advanced BTC treated with chemotherapy, less than 25% received CT2; but responses were seen and were surprisingly high even in this selected population. Pts with a longer TTP on CT1 were more likely to be offered CT2. Better disease control with CT2 occurs with a doublet than single agent, however clearly more effective therapies must be found. Updated data will be presented. [Table: see text]
Associations between nonalcoholic fatty liver disease and obstructive sleep apnea syndrome
Authors: Wanyong Ma, Xiaoguang Yao, Juhong Zhang, Ruimei Han, Na Lin, Dan Shao, Feiya Zu
Journal: BMJ (2014)

Objective
To explore the relativity of nonalcoholic fatty liver disease(NAFLD)and obstructive sleep apnea syndrome (OSAHS).


Methods
A total of 1 693 patients were randomly recruited from 2005 to 2009 from in-hospital hypertensive patients checked by polysomnography (PSG) at our Sleep Center. Among them, 841 patients were diagnosed with fatty liver and another 852 non-fatty liver by type B ultrasound. The subjects underwent PSG and were divided into 4 groups according to apnea-hypopnea index (AHI). The indices of NAFLD and non-NAFLD groups, including age, gender, abdominal girth, body mass index (BMI), apnea hypopnea index (AHI), lowest arterial oxygen saturation, total cholesterol (TC), triglyceride (TG), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C) and fasting blood-glucose(FBG), were analyzed.


Results
Gender, age, TC[(4.5±1.0) vs.(4.4±0.9) mmol/L], TG[(2.4±2.0) vs.(2.1±1.8) mmol/L], LDL-C [(2.69±0.76) vs.(2.60±0.75) mmol/L], FBG [(5.3±1.4) vs.(5.0±1.1) mmol/L], ALT[(33±23) U/L vs.(30±21)U/L]and LDH[(169±37) vs.(163±36) U/L]α-HDBH [(134±29) vs.(130±29) U/L] had significant differences between OSAHS and non-OSAHS groups (P<0.05). The proportion of fatty liver was 52.3% in OSAHS group versus 40.9% in non-OSAHS group. Patients in severe OSAHS group had a higher detection rate of NAFLD than the other three groups (P<0.05). Multivariate logistic regression suggested that AHI, BMI, FBG, TC and TG/HDL-C were risk factors of fatty liver(P<0.05)while age was a protective factor(P<0.05).


Conclusion
There are correlations between OSAHS and NAFLD. And patients in severe OSAHS group have a higher detection rate of NAFLD.


Key words: 
Sleep apnea syndromes; Fatty liver; Association studies
Cyclin D1 (CCND1) mRNA Expression Assessed by Real-Time PCR Is Increased in Patients with Mantle Cell Lymphoma and Contributes to Diagnosis in B-Cell Lymphoma Cases
Authors: Ulrike Bacher, Wolfgang Kern, Claudia Haferlach, Tamara Alpermann, Torsten Haferlach, Susanne Schnittger
Journal: Blood (2012)
p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma
Authors: Teru Hideshima, Francesca Cottini, Yoshihisa Nozawa, Hyuk-Soo Seo, Hiroto Ohguchi, Mehmet K. Samur, Diana Cirstea, Naoya Mimura, Yoshikazu Iwasawa, Paul G. Richardson, Nikhil C. Munshi, Dharminder Chauhan, Walter Massefski, Teruhiro Utsugi, Sirano Dhe-Paganon, Kenneth C. Anderson
Journal: Blood (2017)
Treatment with the PI3K/mTOR Inhibitor, NVP-BEZ235, Overcomes Resistance to Imatinib in Quiescent or T315I-Mutated Ph+ Leukemia Cells,
Authors: Yosuke Minami, Miho Minami, Nobuaki Fukushima, Yachiyo Kuwatsuka, Tomoki Naoe
Journal: Blood (2011)
Longer Time to the Start of Continuation Therapy Is Associated with Improved Survival In High Risk Pediatric Acute Lymphoblastic Leukemia (ALL): A Report From the Children's Oncology Group (COG)
Authors: Marla H Daves, Stephen Hunger, Stephen B Linda, W. Paul Bowman, Nita L. Seibel, Lillian Sung, Meenakshi Devidas
Journal: Blood (2010)
A Multicenter Randomized Comparison of Maintenance Treatment with Androgens in Elderly Acute Myeloid Leukemia after ICL Regimen as Induction Therapy: Results of the Goelams-2002 Study.
Authors: Arnaud Pigneux, Chantal Himberlin, Mathilde Hunault-Berger, Francis Witz, Christian Recher, Jean-Luc Harousseau, Olivier Tournilhac, Chistian Berthou, Martine Escoffre-Barbe, Denis Guyotat, Nathalie Fegueux, Martine Delain, Bruno Lioure, Frédéric Bauduer, Eric Jourdan, Didier Bouscary, Laurence Legros, Frédéric Perry, Noel-Jean Milpied, Marie-Christine Bene, Norbert Ifrah, Jean-Jacques Sotto
Journal: Blood (2006)
Plasma Cell Proliferation Using Ki67 Antigen Expression Defines Subgroups Related to Short Survival in Multiple Myeloma Especially with Low Beta-2 Microglobulin.
Authors: Thomas Gastinne, Xavier Leleu, Anne-Sophie Moreau, Joris Andrieux, Jean-Luc Lai, Valérie Coiteux, Ibrahim Yakoub-Agha, Francis Bauters, Philippe Moreau, Jean-Luc Harousseau, Thierry Facon, Marc Zandecki
Journal: Blood (2006)
Assessment of Serum Bioactive Hepcidin-25, Soluble Transferrin Receptor and Their Ratio in Predialysis Patients: Correlation with the Response to Intravenous Ferric Carboxymaltose Administration
Authors: Athina Drakou, Christos Poziopoulos, Alexandra Margeli, Ioannis Papassotiriou, Demetrios Vlahakos
Journal: Blood (2015)
Clinical Features, Response to Treatment, and Outcomes of IgG4-Related Sclerosing Cholangitis
Authors: Atsushi Tanaka, Susumu Tazuma, Kazuichi Okazaki, Takahiro Nakazawa, Kazuo Inui, Tsutomu Chiba, Hajime Takikawa
Journal: Clinical Gastroenterology and Hepatology (2017)
18F-FDG PET/CT Imaging in Adrenal Cryptococcosis
Authors: Tarun Kumar Jain, Sellam Karunanithi, Chandrasekhar Bal, Rakesh Kumar
Journal: Clinical Nuclear Medicine (2017)

Cryptococcosis is a fungal infection, relatively rare in the absence of impaired immunity. Lung or brain may be involved. Cryptococcal dissemination is rare in absence of impaired immunity, and documentation of alone adrenal involvement without central nervous system involvement is rare. Here, we present a case of an immunocompetent patient presented with bilateral adrenal cryptococcosis with adrenal insufficiency, without central nervous system involvement and 18F-FDG PET/CT correctly identified the residual disease.
Ten Year Survivors of Multiple Myeloma Demonstrate a Differential Expression of Immunological Biomarkers Including a High Incidence of Cytotoxic T-Cell Clones Which Have Not Acquired Myeloma-Associated Anergy,
Authors: Christian E Bryant, Ross D Brown, Shihong Yang, Hayley Suen, Esther Aklilu, James Favaloro, Derek NJ Hart, Phillip Fromm, Narelle Woodland, Najah Nassif, Harry Iland, John Gibson, P Joy Ho, Douglas E Joshua
Journal: Blood (2011)
Disease Progression and Complications Are the Main Cause of Death in Patients with Chronic Lymphocytic Leukemia (CLL) Independent of Age and Comorbidities at Diagnosis
Authors: Paolo Strati, Kari Chaffee, Sara Achenbach, Susan M. Schwager, Timothy G. Call, Neil E. Kay, James Cerhan, Susan L. Slager, Tait D. Shanafelt
Journal: Blood (2015)
Allogeneic Related Donor Hematopoietic Cell Transplantation in AML CR1: Beware of Past Invasive Fungal Infections
Authors: Mutlu Arat, Tulay Ozcelik, Serkan Guvenc, Fehmi Hindilerden, Hasan Sami Goksoy, Reyhan Küçükkaya
Journal: Blood (2014)
TCT-60 Clinical and Procedural Outcomes of Renal Artery Denervation In Real World Patients with Hypertension: An Update From the Global SYMPLICITY Registry
Authors: Felix Mahfoud, Giuseppe Mancia, Markus P. Schlaich, Krzysztof Narkiewicz, Luis Ruilope, Bryan Williams, Roland E. Schmieder, Michael Bohm
Journal: Journal of the American College of Cardiology (2013)
Improvement in Outcome of Patients with CD30+ HIV-Related Systemic B-Cell Non-Hodgkin’s Lymphoma (NHL) Providing HIV Infection Is Adequately Controlled.
Authors: Hatoon Ezzat, Jonathan C. Wong, Douglas Filipenko, Linda M. Vickars, Paul F. Galbraith, Charles H. Li, Kevin Murphy, Julio S.G. Montaner, Marianne Harris, Robert S. Hogg, Suzanne Vercauteren, Chantal S. Leger, Leslie Zypchen, Heather A. Leitch
Journal: Blood (2006)
Citron Rho-Interacting Serine/Threonine kinase (CIT) Is a Novel Therapeutic Target in Multiple Myeloma Cells
Authors: Yawara Kawano, Ilyas Sahin, Michele Moschetta, Jinhua Wang, Salomon Manier, Siobhan Glavey, Yuji Mishima, Katsutoshi Kokubun, Shokichi Tsukamoto, Antonio Sacco, Kenneth C. Anderson, Aldo M Roccaro, Nathanael S. Gray, Irene M. Ghobrial
Journal: Blood (2014)
Avelumab (MSB0010718C; anti-PD-L1) vs platinum-based doublet as first-line treatment for metastatic or recurrent PD-L1-positive non-small-cell lung cancer: The phase 3 JAVELIN Lung 100 trial.
Authors: Martin Reck, Hyatt P. DeGreen, Andrea L. Rose, Nick Pavlakis, Sofie Maria Derjcke, Jasna Radic, Nina Jeppesen, Michael Thomas, Gyorgy Losonczy, Ewa Kalinka-Warzocha, Lydia Mary Dreosti, Mustafa Ozguroglu, Pieter E. Postmus, Christoph Helwig, Vikram Chand, Jean-Marie Cuillerot, Virginie Westeel
Journal: Journal of Clinical Oncology (2016)

TPS9105 Background: Programmed death-1 receptor ligand (PD-L1) is a key therapeutic target in the reactivation of the immune response against multiple cancers. Avelumab* is a fully human anti-PD-L1 IgG1 antibody that has shown promising efficacy and an acceptable safety profile in multiple tumor types, including non-small-cell lung cancer (NSCLC). This open-label phase 3 trial (NCT02576574) compares single-agent avelumab vs platinum-based doublet chemotherapy as first-line treatment for patients (pts) with PD-L1-positive (+) recurrent or stage IV NSCLC negative for activating EGFR mutation and ALK translocation. Methods: The primary objective of this global, multicenter, randomized trial is to demonstrate superiority of avelumab in improving progression-free survival (PFS) according to RECIST 1.1 and as assessed by an Independent Review Committee (IRC) vs platinum-based doublet chemotherapy. Approximately 420 pts with PD-L1+ tumors, as determined by companion diagnostic assay, will be randomized. Eligibility criteria include: histologically confirmed metastatic or recurrent NSCLC, ECOG PS 0-1, no prior systemic treatment for recurrent/metastatic NSCLC, no prior therapy with any drug targeting T cell coregulatory proteins, no concurrent anticancer treatment or immunosuppressive agents, and known EGFR mutation/ALK translocation-negative tumor. Pts receive either avelumab 10 mg/kg as a 1h intravenous (IV) infusion Q2W or a platinum-based doublet (non-squamous histology: pemetrexed 500 mg/m2 + cisplatin 75 mg/m2 or carboplatin AUC 6; squamous histology: paclitaxel 200 mg/m2 + carboplatin AUC 6, gemcitabine 1250 mg/m2 + cisplatin 75 mg/m2, or gemcitabine 1000 mg/m2 + carboplatin AUC 5) by IV infusion. Treatment is given until disease progression, unacceptable toxicity, or consent withdrawal, with a maximum of 6 cycles of chemotherapy. Secondary endpoints include objective response rate, overall survival, quality of life (assessed via EQ-5D, EORTC QLQ-C30, and EORTC QLQ-LC13), safety as per NCI-CTCAE v4.03, and tumor biomarkers. Trial enrollment began in Oct 2015. *Proposed INN. Clinical trial information: NCT02576574.
Selective Inhibition of CDK4 and CDK6 Primes Chemoresistant Myeloma Cell for Cytotoxic Killing through Induction of Cell Cycle-Coupled Mitochondrial Dysfunction and Apoptosis
Authors: Xiangao Huang, Maurizio Di Liberto, Tracey Louie, David S Jayabalan, Scott Ely, Ruben Niesvizky, Selina Chen-Kiang
Journal: Blood (2008)
Precise Spatially Selective Photothermolysis Using Modulated Femtosecond Lasers and Real-time Multimodal Microscopy Monitoring
Authors: Yimei Huang, Harvey Lui, Jianhua Zhao, Zhenguo Wu, Haishan Zeng
Journal: Theranostics (2017)

The successful application of lasers in the treatment of skin diseases and cosmetic surgery is largely based on the principle of conventional selective photothermolysis which relies strongly on the difference in the absorption between the therapeutic target and its surroundings. However, when the differentiation in absorption is not sufficient, collateral damage would occur due to indiscriminate and nonspecific tissue heating. To deal with such cases, we introduce a novel spatially selective photothermolysis method based on multiphoton absorption in which the radiant energy of a tightly focused near-infrared femtosecond laser beam can be directed spatially by aiming the laser focal point to the target of interest. We construct a multimodal optical microscope to perform and monitor the spatially selective photothermolysis. We demonstrate that precise alteration of the targeted tissue is achieved while leaving surrounding tissue intact by choosing appropriate femtosecond laser exposure with multimodal optical microscopy monitoring in real time.
Serum Soluble Interleukin-2 Level Determines Clinical Outcome In Patients with Follicular Lymphoma In Rituximab Era
Authors: Senji Kasahara, Naoe Goto, Hisashi Tsurumi, Nobuhiro Nakamura, Hiroshi Nakamura, Nobuhiro Kanemura, Takeshi Hara, Tsuyoshi Takami, Hisataka Moriwaki
Journal: Blood (2010)
Subcutaneous Versus Intravenous Bortezomib in Two Different Induction Therapies for Newly Diagnosed Multiple Myeloma – Subgroup Analysis from the GMMG-MM5 Trial
Authors: Maximilian Merz, Hans Salwender, Mathias Hänel, Uta Bertsch, Christina Kunz, Thomas Hielscher, Igor W. Blau, Christof Scheid, Elias Karl Mai, Dirk Hose, Baerbel Schurich, Markus Munder, Ingo GH Schmidt-Wolf, Christian Gerecke, Hans Walter Lindemann, Matthias Zeis, Katja Weisel, Jan Duerig, Hartmut Goldschmidt
Journal: Blood (2014)
Hedgehog Pathway as a Potential Therapeutic Target in Multiple Myeloma.
Authors: Simona Blotta, Joeseph Negri, Purushothama Nanjappa, Anne-Sophie Moreau, Rao Prabhala, Masood Shammas, Dheeraj Pelluru, Douglas McMillin, Yu-Tzu Tai, Pierfrancesco Tassone, Kenneth C. Anderson, Constantine Mitsiades, Nikhil C. Munshi
Journal: Blood (2007)
Hypercalcemia Following Treatment with Lenalidomide in Chronic Lymphocytic Leukemia (CLL).
Authors: Bijal D. Shah, Marays Veliz, Ricardo Santana, Jeffrey E Lancet, John J. Powers, Jason A Dubovsky, Sara Tinsley, Darcie Deaver, Eduardo M. Sotomayor, Javier Pinilla
Journal: Blood (2009)
Outcomes of Previously Untreated Older Patients with Multiple Myeloma (MM) over Time: An Analysis of 3 Consecutive Trials Conducted by the NCIC CTG, 1983–2003.
Authors: Cynthia Luk, Keyue Ding, Andrew R. Belch, George P. Browman, Chaim Shustik, Marina Djurfeldt, Dianne Johnston, Lois E. Shepherd, Ralph M. Meyer
Journal: Blood (2005)
AML with Translocation T(8;16) Shows Unique Cytomorphological, Cytogenetic, Molecular, and Prognostic Features and Therefore Qualifies as An Own Entity According to WHO Criteria.
Authors: Alexander Kohlmann, Martin Dugas, Hans-Ulrich Klein, Christian Ruckert, Wolfgang Kern, Susanne Schnittger, Helmut Löffler, Claudia Haferlach, Torsten Haferlach
Journal: Blood (2008)
OSU-2S, A Novel FTY720 derivative, Mediates Cytotoxicity In Chronic Lymphocytic Leukemia Through PKC Dependent Modulation of SHP1 Tyrosine Phosphatase
Authors: Rajeswaran Mani, Frank W Frissora, Ching-Shih Chen, John C. Byrd, Natarajan Muthusamy
Journal: Blood (2011)
Seed plant specific gene lineages involved in carpel development
Authors: Kai C. Pfannebecker, Matthias Lange, Oliver Rupp, Annette Becker
Journal: Molecular Biology and Evolution (2016)

Evolutionary innovations are important drivers of speciation and some are the defining characters of entire phyla. One such major innovation is the carpel, the unifying character and most complex plant organ, composed of many clearly distinct tissue types to ensure reproductive success. The origin of the carpel is unknown, but many components of the gene regulatory network (GRN) governing carpel development and their genetic interactions are known from the core eudicot Arabidopsis thaliana. To unravel the evolution of the carpel GRN and to discriminate between "early" and "late" steps in carpel evolution, we calculated thorough phylogeny reconstructions based on sequenced genomes. The A. thaliana carpel GRN members ALCATRAZ (ALC), CRABS CLAW (CRC), HALF FILLED (HAF), HECATE (HEC), INDEHISCENT (IND), NGATHA (NGA), and SPATULA (SPT) were analyzed in their phylogenetic context. We find that the carpel GRN components are of various ages, but interestingly, we identify especially high retention rates for carpel development genes in Brassicaceae. Our data suggest that genes whose A. thaliana homologs are involved in processes already present in the most recent common ancestor of seed plants, such as reproductive meristem termination or adaxial/abaxial polarity specification, are not retained in duplicates after whole genome duplications (WGD). In contrast, genes involved in processes associated with derived carpel characters in Arabidopsis, such as the transmitting tract or style development show a higher gene retention rate after WGD. This work provides a starting point for analyses of carpel genes in early diverging angiosperms which would be very informative for evolutionary studies.
Suppression of RISC-Independent Decoy and RISC-Mediated mRNA Base-Pairing Activities of MicroRNA-328 Is Required for Differentiation-Arrest and Enhanced Survival of Blast Crisis CML Progenitors.
Authors: Anna M Eiring, Jason Harb, Paolo Neviani, Joshua Oaks, Shujun Liu, Riccardo Spizzo, Sebastian Schwind, Ramasamy Santhanam, Christopher Hickey, Heiko Becker, Jason C. Chandler, Raul Andino, Jorge Cortes, Peter Hokland, Claudia Huettner, Ravi Bhatia, Denis-Claude Roy, Stephen Liebhaber, Michael A. Caligiuri, Guido Marcucci, Ramiro Garzon, Carlo M. Croce, George A Calin, Danilo Perrotti
Journal: Blood (2009)
Regulation of Immune Responses during Acute GvHD Via the IL-33/ST2 Axis
Authors: Dawn K Reichenbach, Vincent Schwarze, Benjamin M Matta, Victor Tkachev, Elizabeth Lieberknecht, Quan Liu, Brent H Koehn, Dietmar Pfeifer, Patricia A Taylor, Gabriele Prinz, Heide Dierbach, Natalie Stickel, Yvonne Beck, Max Warncke, Tobias Junt, Annette Schmitt-Graeff, Susumu Nakae, Marie Follo, Tobias Wertheimer, Lukas Schwab, Jason Devlin, Simon C Watkins, Justus Duyster, James L.M. Ferrara, Heth R. Turnquist, Robert Zeiser, Bruce R. Blazar
Journal: Blood (2014)
Preserved Renal-Allograft Function and the PD-1 Pathway Inhibitor Nivolumab
Authors: Richard Barnett, Valerie S Barta, Kenar D Jhaveri
Journal: New England Journal of Medicine (2017)

To the Editor: Inhibition of immune checkpoints with the use of antibodies targeting programmed cell death 1 (PD-1) or monoclonal antibodies against cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) has been used clinically in patients with various types of cancer. In the limited number of reported cases in which these antibodies have been used in patients who have undergone kidney transplantation,1 these agents have been associated with cell-mediated and antibody-mediated rejection (see Table S2 in the Supplementary Appendix, available with the full text of this letter at NEJM.org). We report on a patient who received a renal transplant from a living related donor. . . .
Reduced-Intensity Conditioning (RIC) Prior to Allogeneic Stem Cell Transplantation (allo-SCT) In Pediatric Patients Ineligible for Standard Myeloablative Conditioning.
Authors: M. Strullu, Fanny Rialland, Eolia Brissot, N. Corradini, Caroline Thomas, Francoise Mechinaud, Mohamad Mohty
Journal: Blood (2010)